ATE485823T1 - Kombinationspräparate enthaltend (e)-7-ä4-(4- fluorophenyl)-6-isopropyl-2- - Google Patents

Kombinationspräparate enthaltend (e)-7-ä4-(4- fluorophenyl)-6-isopropyl-2-

Info

Publication number
ATE485823T1
ATE485823T1 AT07008956T AT07008956T ATE485823T1 AT E485823 T1 ATE485823 T1 AT E485823T1 AT 07008956 T AT07008956 T AT 07008956T AT 07008956 T AT07008956 T AT 07008956T AT E485823 T1 ATE485823 T1 AT E485823T1
Authority
AT
Austria
Prior art keywords
fluorophenyl
isopropyl
preparations containing
combination preparations
combination
Prior art date
Application number
AT07008956T
Other languages
English (en)
Inventor
Norman Eugene Cameron
Mary Anne Cotter
Original Assignee
Astrazeneca Ab
Univ Aberdeen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9902594.2A external-priority patent/GB9902594D0/en
Priority claimed from GBGB9902591.8A external-priority patent/GB9902591D0/en
Application filed by Astrazeneca Ab, Univ Aberdeen filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE485823T1 publication Critical patent/ATE485823T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT07008956T 1999-02-06 2000-02-01 Kombinationspräparate enthaltend (e)-7-ä4-(4- fluorophenyl)-6-isopropyl-2- ATE485823T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9902594.2A GB9902594D0 (en) 1999-02-06 1999-02-06 Pharmaceutical compositions
GBGB9902591.8A GB9902591D0 (en) 1999-02-06 1999-02-06 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ATE485823T1 true ATE485823T1 (de) 2010-11-15

Family

ID=26315085

Family Applications (2)

Application Number Title Priority Date Filing Date
AT07008956T ATE485823T1 (de) 1999-02-06 2000-02-01 Kombinationspräparate enthaltend (e)-7-ä4-(4- fluorophenyl)-6-isopropyl-2-
AT00901744T ATE367162T1 (de) 1999-02-06 2000-02-01 Verwendubg von 3-hydroxy-3-methylglutaryl coenzym a reduktase inhibitoren zur herstellung eines medikaments zur behandlung der diabetischen neuropathie

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00901744T ATE367162T1 (de) 1999-02-06 2000-02-01 Verwendubg von 3-hydroxy-3-methylglutaryl coenzym a reduktase inhibitoren zur herstellung eines medikaments zur behandlung der diabetischen neuropathie

Country Status (34)

Country Link
US (4) US6894058B1 (de)
EP (2) EP1150678B1 (de)
JP (3) JP2002536332A (de)
KR (1) KR100699757B1 (de)
CN (1) CN1196488C (de)
AR (1) AR025512A1 (de)
AT (2) ATE485823T1 (de)
AU (1) AU763970B2 (de)
BR (1) BR0007996A (de)
CA (1) CA2368186C (de)
CY (2) CY1106879T1 (de)
CZ (2) CZ302893B6 (de)
DE (2) DE60035575T2 (de)
DK (2) DK1897546T3 (de)
EE (2) EE05556B1 (de)
ES (2) ES2352803T3 (de)
GB (1) GB0001662D0 (de)
HK (2) HK1041223A1 (de)
HU (1) HU227642B1 (de)
IL (3) IL144730A0 (de)
IS (2) IS2793B (de)
MX (1) MXPA01007821A (de)
MY (1) MY138289A (de)
NO (1) NO330400B1 (de)
NZ (3) NZ536433A (de)
PL (1) PL198098B1 (de)
PT (2) PT1897546E (de)
RU (1) RU2239456C2 (de)
SI (2) SI1897546T1 (de)
SK (2) SK286854B6 (de)
TR (1) TR200102229T2 (de)
TW (1) TWI230067B (de)
WO (1) WO2000045818A1 (de)
ZA (1) ZA200105885B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6555540B1 (en) * 1999-06-30 2003-04-29 Pfizer Inc Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
US20030060488A1 (en) * 2000-02-10 2003-03-27 Yasuo Sugiyama Drug comprising combination
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
DE10025308A1 (de) * 2000-05-23 2001-11-29 Bayer Ag Kombination von Cerivastatin mit ACE Inhibitoren und ihre Verwendung in Arzneimitteln
AR030379A1 (es) * 2000-08-22 2003-08-20 Novartis Ag Combinaciones
US20060089389A1 (en) 2000-08-22 2006-04-27 Malcolm Allison Combination
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
PL361097A1 (en) * 2000-10-12 2004-09-20 Nissan Chemical Industries, Ltd. Preventives and remedies for complications of diabetes
AU2001276645A1 (en) * 2000-10-18 2002-04-29 Pfizer Products Inc. Combination of statins and sorbitol dehydrogenase inhibitors
BR0115776A (pt) 2000-11-30 2004-01-13 Pfizer Prod Inc Combinações de agonistas de gaba e inibidores da aldose redutase
US20030171407A1 (en) * 2002-03-07 2003-09-11 Upsher-Smith Laboratories, Inc. Composition for reducing blood glucose and cholesterol
US20030199424A1 (en) * 2002-03-20 2003-10-23 Smith Maree Therese Method of treatment and/or prophylaxis
PE20040291A1 (es) * 2002-03-22 2004-07-02 Novartis Ag COMBINACION QUE COMPRENDE UN INHIBIDOR DE HMG-CoA-REDUCTASA Y UN POTENCIADOR DE LA SECRECION DE INSULINA Y/O UN SENSIBILIZANTE DE INSULINA
JP4395633B2 (ja) * 2002-08-29 2010-01-13 学校法人鈴鹿医療科学大学 非神経細胞の神経細胞への分化成熟法、該組成物と該組成物探索法
US7179941B2 (en) 2003-01-23 2007-02-20 Sanofi-Aventis Deutschland Gmbh Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
DE10302452B4 (de) * 2003-01-23 2005-02-24 Aventis Pharma Deutschland Gmbh Carbonylamino-substituierte Acyl-phenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
JP2005232151A (ja) * 2003-04-28 2005-09-02 Iichiro Shimomura 糖取り込み能増強剤
EP1618893A4 (de) 2003-04-28 2009-08-12 Sankyo Co Mittel zur verstärkung der zuckeraufnahmefähigkeit
AU2004233693B2 (en) * 2003-04-28 2007-07-19 Funahashi, Toru Adiponectin production enhancer
US20090082407A1 (en) * 2004-06-18 2009-03-26 Biostratum, Inc. Pyridoxamine for the Treatment of Diabetic Kidney Disease
US20050014799A1 (en) * 2003-06-20 2005-01-20 Biostratum, Inc. Pyridoxamine for the treatment of diabetic kidney disease
EP1510208A1 (de) * 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Metformin-Statin-Kombination enthaltende pharmazeutische Zusammensetzungen
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
WO2005023766A1 (en) * 2003-09-11 2005-03-17 Biocon Limited Salt of atorvastatin with metformin
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
AU2003272084A1 (en) * 2003-10-07 2005-04-21 Biocon Limited SALT OF 1,2,6,7,8,8A-HEXAHYDRO-Beta,Delta,6-TRIHYDROXY-2-METHYL-8-((2S)-2-METHYL-1-OXOBUTOXY)-, (BetaR,Delta R,1S,2S,6S,8S,8AR)- 1-NAPHTHALENEHEPTANOIC ACID WITH N,N-DIMETHYL-IMIDODICARBONIMIDIC DIAMIDE
KR100715114B1 (ko) * 2005-02-19 2007-05-10 한국유나이티드제약 주식회사 당뇨병 치료를 위한 약학적 조성물
CN101632673B (zh) * 2008-07-24 2011-08-10 鲁南制药集团股份有限公司 含有氯沙坦、吡格列酮和瑞舒伐他汀的药物组合物及其新用途
LT2326632T (lt) * 2008-09-06 2017-09-25 Bionevia Pharmaceuticals, Inc. Naujas epalrestato cholino kokristalas
EP2196476A1 (de) 2008-12-10 2010-06-16 Novartis Ag Antikörperformulierung
RU2014124118A (ru) 2011-11-15 2015-12-27 Др. Редди'С Лабораторис Лтд. Фармацевтические препараты, включающие аторвастатин и глимепирид
WO2015053589A1 (ko) * 2013-10-11 2015-04-16 가톨릭대학교 산학협력단 메트포민 및 스타틴의 복합제를 이용한 자가면역질환의 예방 또는 치료용 조성물
KR101579656B1 (ko) * 2013-12-12 2015-12-22 가천대학교 산학협력단 프라바스타틴과 발사르탄을 포함하는 약학 조성물
CN110747206B (zh) * 2019-11-05 2021-11-23 昆明理工大学 3-羟基-3-甲基戊二酸单酰辅酶a还原酶基因rkhmgr及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
CA2040865C (en) 1990-05-15 2002-07-23 James L. Bergey Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
US5298497A (en) 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
US5140012A (en) 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin
US5622985A (en) 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
US5130333A (en) * 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
CA2052014A1 (en) * 1990-10-19 1992-04-20 Henry Y. Pan Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5190970A (en) 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
DK0636027T3 (da) 1992-04-13 2000-01-31 Zeneca Ltd Angiotensin-II-antogonister mod sygdomme forbundet med forringet neuronal ledningshastighed, især diabetisk neuropati
GB9208116D0 (en) * 1992-04-13 1992-05-27 Ici Plc Therapeutic agents
WO1995013063A1 (en) 1993-11-09 1995-05-18 Merck & Co., Inc. HMG-CoA REDUCTASE INHIBITORS IN THE NORMALIZATION OF VASCULAR ENDOTHELIAL DYSFUNCTION
CA2186606A1 (en) 1994-03-29 1995-10-05 Edward B. Nelson Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
ATE220333T1 (de) 1996-04-05 2002-07-15 Takeda Chemical Industries Ltd Pharmazeutische kombination enthaltend einen wirkstoff mit angiotensin-ii antagonistischer aktivität und einen wirkstoff der die insulin- sensitivität erhöht
GB9714274D0 (en) * 1997-07-08 1997-09-10 Zeneca Ltd Pharmaceutical composition
GT199800126A (es) 1997-08-29 2000-01-29 Terapia de combinacion.
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6262076B1 (en) * 2000-01-28 2001-07-17 Ajinomoto Co., Inc. Pharmaceutical composition for use in the treatment of diabetic neuropathy
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment

Also Published As

Publication number Publication date
BR0007996A (pt) 2001-10-30
PL350312A1 (en) 2002-12-02
DK1897546T3 (da) 2011-01-17
HUP0105138A2 (hu) 2002-04-29
CN1338937A (zh) 2002-03-06
RU2239456C2 (ru) 2004-11-10
DE60035575D1 (de) 2007-08-30
CY1110992T1 (el) 2015-06-11
KR20010089635A (ko) 2001-10-06
SK11102001A3 (sk) 2002-05-09
JP2002536332A (ja) 2002-10-29
WO2000045818A1 (en) 2000-08-10
CZ20012806A3 (cs) 2002-02-13
CA2368186A1 (en) 2000-08-10
IS8978A (is) 2011-08-23
MXPA01007821A (es) 2004-08-19
IL144730A (en) 2010-12-30
ES2286995T3 (es) 2007-12-16
US20050209128A1 (en) 2005-09-22
IL144730A0 (en) 2002-06-30
ATE367162T1 (de) 2007-08-15
NO20013812D0 (no) 2001-08-03
ES2352803T3 (es) 2011-02-23
US6894058B1 (en) 2005-05-17
HK1118209A1 (en) 2009-02-06
SK286854B6 (sk) 2009-06-05
EP1150678B1 (de) 2007-07-18
ZA200105885B (en) 2002-10-17
GB0001662D0 (en) 2000-03-15
NZ513061A (en) 2003-06-30
CY1106879T1 (el) 2012-05-23
JP2014065718A (ja) 2014-04-17
TR200102229T2 (tr) 2001-12-21
KR100699757B1 (ko) 2007-03-27
CA2368186C (en) 2008-06-03
AU2304700A (en) 2000-08-25
HU227642B1 (en) 2011-10-28
NZ525419A (en) 2004-12-24
US20120041010A1 (en) 2012-02-16
NO20013812L (no) 2001-10-02
EE05556B1 (et) 2012-08-15
JP2012051898A (ja) 2012-03-15
CZ302881B6 (cs) 2012-01-04
EE200100405A (et) 2002-10-15
SK287792B6 (sk) 2011-10-04
EE201200015A (et) 2012-10-15
IS2820B (is) 2012-12-15
EE05621B1 (et) 2013-02-15
AU763970B2 (en) 2003-08-07
NO330400B1 (no) 2011-04-04
EP1897546A1 (de) 2008-03-12
HUP0105138A3 (en) 2002-11-28
IS6016A (is) 2001-07-20
EP1150678A1 (de) 2001-11-07
CN1196488C (zh) 2005-04-13
MY138289A (en) 2009-05-29
HK1041223A1 (en) 2002-07-05
NZ536433A (en) 2006-08-31
PL198098B1 (pl) 2008-05-30
EP1897546B1 (de) 2010-10-27
SI1150678T1 (sl) 2008-02-29
IS2793B (is) 2012-08-15
DE60035575T2 (de) 2008-04-03
IL208330A0 (en) 2010-12-30
SI1897546T1 (sl) 2011-02-28
DK1150678T3 (da) 2007-10-08
US20090186908A1 (en) 2009-07-23
PT1897546E (pt) 2010-12-15
CZ302893B6 (cs) 2012-01-11
PT1150678E (pt) 2007-09-14
DE60045168D1 (de) 2010-12-09
AR025512A1 (es) 2002-12-04
TWI230067B (en) 2005-04-01

Similar Documents

Publication Publication Date Title
ATE485823T1 (de) Kombinationspräparate enthaltend (e)-7-ä4-(4- fluorophenyl)-6-isopropyl-2-
IS6040A (is) Valdekoxib efnablöndur
IS5953A (is) Lyfjablöndur úr örgerðum eplerenonum
NO2010019I2 (no) 6-per-deoksy-6-per-(2-karboksetyl)tio-y-cyklodextrin
NO992339L (no) Farmasöytiske formuleringer
DK1210113T3 (da) Kombinerede vaccinepræparater
DE60011853D1 (de) Injektionsspritze
DE60020343D1 (de) Cilostazol enthaltende zubereitung
DE69834019D1 (de) Dose
ATE224703T1 (de) Brauseformulierungen
NO20014490D0 (no) Medisinske blandinger
NO20006191D0 (no) Vaksine
DE69919784D1 (de) Spritze
PT1173187E (pt) Preparacoes combinadas compreendendo derivados de antraciclina
EE200200150A (et) Preparaat
EE05375B1 (et) LevosimendaniÁfarmatseutilineÁlahus
IS6398A (is) Lyfjablöndur
DE69935609D1 (de) Formulierungen enthaltend cefuroxim-axetil
DE69926012D1 (de) Arzneizubereitungen
ATE246494T1 (de) Brausezubereitungen
NO20005599D0 (no) Vaksine
DE29817592U1 (de) Dose
DE69906934D1 (de) Arzneizubereitungen
DE50009295D1 (de) Vernetzerfreie zubereitungen
DE60020365D1 (de) Säurekatalysierte umsetzungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1897546

Country of ref document: EP